Isabella Faraoni

6PUBLICATIONS
14CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 10, 2025
PML::RARĪ±+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias.

Alessandra Zaza, Giuseppe Zardo, Cristina Banella

|Jan 24, 2025
Polydatin-Induced Shift of Redox Balance and Its Anti-Cancer Impact on Human Osteosarcoma Cells.

Alessio Cimmino, Magda Gioia, Maria Elisabetta Clementi

|Nov 27, 2024
Combination Treatment of Resistant Acute Promyelocytic Leukemia Cells with Arsenic Trioxide and Anti-Apoptotic Gene Inhibitors.

Manuela Giansanti, Tiziana Ottone, Serena Travaglini

|Oct 13, 2021
Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?

Ornella Franzese, Francesco Torino, Elisa Giannetti

|Apr 06, 2021
Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.

Manuela Giansanti, Antonio De Gabrieli, Salvatore Pasquale Prete

|Apr 03, 2021
High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients.

Manuela Giansanti, Terry Karimi, Isabella Faraoni

Pageof 1

Frequent Collaborators

3 joint publications

Grazia Graziani

2 joint publications

Manuela Giansanti

2 joint publications

Serena Travaglini

2 joint publications

Maria Teresa Voso